Outcomes in patients with <i>ETV6</i>::<i>RUNX1</i> or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies
Katelyn N. Purvis(St. Jude Children's Research Hospital), Hiroto Inaba(St. Jude Children's Research Hospital), Qingsong Gao(St. Jude Children's Research Hospital), Ching‐Hon Pui(St. Jude Children's Research Hospital), Shawn H.R. Lee(National University of Singapore), Sima Jeha(St. Jude Children's Research Hospital), Yinmei Zhou(St. Jude Children's Research Hospital), Kathryn G. Roberts(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Jun J. Yang(St. Jude Children's Research Hospital), Jeffrey E. Rubnitz(St. Jude Children's Research Hospital), Stephanie B. Dixon(St. Jude Children's Research Hospital), Raul C. Ribeiro(St. Jude Children's Research Hospital), Cheng Cheng(Jilin University), Seth E. Karol(St. Jude Children's Research Hospital), Lu Wang(The Central Hospital of Xiao gan), W. Paul Bowman(St. Jude Children's Research Hospital)
Cited by 17
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k